cGAS - STING通路
Search documents
中国药科大学最新Science子刊:开发新型乳腺癌疫苗
生物世界· 2025-11-24 04:28
撰文丨王聪 编辑丨王多鱼 排版丨水成文 免疫原性细胞死亡 ( Immunogenic cell death, ICD) 是一种很有前景的方法,可用于激发抗肿瘤免疫反应,从而治疗癌症患者。然而,免疫原性细胞死亡的 立体定向诱导以及肿瘤特异性免疫反应的时空同步激活,构成了两大关键挑战。 2025 年 11 月 19 日,中国药科大学 尹骏 、 高向东 、 童玥 等人在 Science 子刊 Science Translational Medicine 上发表了题为: A modular metalloprotein in situ vaccine for cancer immunotherapy in mouse models of breast cancer 的研究论文。 在这项最新研究中,研究团队报道了一种 蛋白酶激活的 聚多肽 (PSTAG) 修饰的 原位肿瘤疫苗 (PPTV) 的模块化金属蛋白平台的基本原理和系统性开发。 研究团队利用铁蛋白作为疫苗框架,其外表面融合了最佳线粒体破坏肽,内腔装载锰离子 (Mn²⁺) 。此外,研究团队开发了蛋白酶激活的 PSTAG 修饰的前药策 略,以规避铁蛋白相关的主要问题 ...
Mol Cell 封面论文:王晓东院士团队揭示程序性坏死引发炎症的新机制
生物世界· 2025-07-05 23:58
Core Viewpoint - The study reveals that MLKL activates the cGAS-STING pathway by releasing mitochondrial DNA (mtDNA) during necroptosis, leading to the upregulation of interferon β (Ifnb) expression and inflammation, independent of cell membrane rupture [3][10]. Group 1: Mechanism of Necroptosis - Necroptosis is a pro-inflammatory and lytic form of programmed cell death executed by the MLKL protein, which is phosphorylated by RIPK3, causing membrane rupture and the release of damage-associated molecular patterns (DAMPs) [2]. - Phosphorylated MLKL (pMLKL) also translocates to mitochondria, inducing microtubule-dependent mtDNA release, which activates the cGAS-STING pathway [7][8]. - The integrity of microtubules is essential for the release of mtDNA into the cytoplasm [8]. Group 2: Implications for Inflammatory Bowel Disease (IBD) - In a mouse model of IBD mediated by necroptosis, inhibiting the STING pathway accelerates the resolution of intestinal inflammation [3][10]. - The study enhances understanding of necroptosis and its implications for IBD treatment, suggesting that targeting the cGAS-STING pathway may provide therapeutic benefits [10].
Immunity:衰老癌细胞释放线粒体DNA,破坏抗肿瘤免疫
生物世界· 2025-05-12 04:15
Core Viewpoint - Cellular senescence is a stable state of growth arrest closely related to age-related diseases and cancer development, characterized by an intrinsic anti-apoptotic ability and a unique secretory phenotype known as the senescence-associated secretory phenotype (SASP) [1][2]. Group 1 - Senescent tumor cells release mitochondrial DNA (mtDNA), which enhances immunosuppression mediated by polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) through the cGAS-STING pathway [3][9]. - The release of mtDNA from senescent cells can exacerbate inflammation associated with tissue damage or disease progression, indicating a potential mechanism linking cellular senescence to age-related diseases and cancer [2][6]. - The study highlights that targeting the release of mtDNA could reprogram the immunosuppressive tumor microenvironment, thereby improving cancer treatment outcomes for patients undergoing chemotherapy [9][10]. Group 2 - The research team found that both naturally senescent primary cells and tumor cells undergoing senescence due to treatment actively release mtDNA into the extracellular environment [5][7]. - Extracellular mtDNA is encapsulated in extracellular vesicles and selectively transferred to PMN-MDSC, enhancing their immunosuppressive activity through the cGAS-STING-NF-κB signaling pathway [5][10]. - Pharmacological inhibition of voltage-dependent anion channels (VDAC) can reduce extracellular mtDNA levels and reverse PMN-MDSC-driven immunosuppression, improving chemotherapy efficacy in prostate cancer mouse models [6][10].